Arsenic trioxide as primary treatment in acute promyelocytic leukemia
<jats:p> 16533 </jats:p><jats:p> Acute Promyelocytic Leukemia (APL) is a separate, distinct and biologically unique subset of Acute Myelogenous Leukemia (AML). The affordability of ATRA is detrimental for its use especially in the developing world. The use of Arsenic trioxide (As2O...
|Journal Title:||Journal of Clinical Oncology|
|Authors and Corporations:|
|In:||Journal of Clinical Oncology, 24, 2006, 18_suppl, p. 16533-16533|
|Type of Resource:||E-Article|
American Society of Clinical Oncology (ASCO)